Amgen's MariTide Shows Promising Phase 2 Results in Obesity Treatment
核心洞察
Amgen's MariTide (maridebart cafraglutide) demonstrated positive results in a Phase 2 study for obesity (搜索) treatment over 52 weeks.
The study results and progress on the MariTide development program will be discussed in an upcoming webcast hosted by Amgen.
Amgen is leveraging advanced human genetics to develop innovative therapeutics for serious illnesses with high unmet medical needs.
Amgen (NASDAQ:AMGN) is set to host a webcast on November 26, 2024, to discuss the Phase 2 study results of MariTide (maridebart cafraglutide, formerly AMG 133) and provide updates on its development program. The 52-week Phase 2 study evaluated MariTide's efficacy and safety in treating obesity (搜索).
MariTide: A Novel Approach to Obesity Treatment
MariTide represents a novel therapeutic approach, leveraging Amgen's expertise in human genetics to address the complexities of obesity (搜索). Amgen focuses on areas of high unmet medical need, striving to improve health outcomes and significantly enhance patients' lives through innovative solutions.
Webcast Details
The webcast will feature Robert A. Bradway, chairman and chief executive officer, along with other members of Amgen's senior management team. The live audio webcast will be accessible to the news media, investors, and the general public via Amgen's Investor Relations Events Calendar on their website. An archived replay will be available for at least 90 days following the event.
Amgen's Commitment to Innovation
Amgen is dedicated to unlocking the potential of biology for patients suffering from serious illnesses. As a biotechnology pioneer since 1980, Amgen has grown into one of the world's leading independent biotechnology companies, reaching millions of patients globally and developing a pipeline of medicines with significant potential.